Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen
peptide vaccine strategy in pancreatic cancer patients following surgical resection and
adjuvant chemotherapy. The neoantigen peptide vaccines will incorporate prioritized
neoantigens and personalized mesothelin epitopes and will be co-administered with poly-ICLC.
The hypothesis of this study is that neoantigen peptide vaccines will be safe and capable of
generating measurable neoantigen-specific CD4 and CD8 T cell responses.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)